Heng Lab
330 Brookline Ave
Boston MA 02115
Bridging the gap between molecular biology and clinical utility
Our research programs are unified by a single focus: understanding breast cancer biology across the disease continuum. From identifying the earliest tissue changes to decoding the intrinsic factors governing therapeutic response, we design the tools that define the future of oncology.
Recent Publications
- The miR-362-3p/BCLAF1 axis regulates cisplatin sensitivity and metastatic progression in triple-negative breast cancer
- MicroRNA spatial profiling for assessing drug efficacy in BRCA1-related triple-negative breast tumors
- Genomic and Transcriptomic Landscape and Determinants of Response of BRCA-related Breast Cancers Treated with Neoadjuvant Chemotherapy (TBCRC 031)
- Associations of stromal markers’ expression in benign breast tissue with subsequent breast cancer risk.
- Masculinizing Testosterone Therapy Reduces the Incidence of PIK3CA-Mutant/ER+ Breast Cancer but Not BRCA1-Associated Triple-Negative Breast Cancer
- Simultaneous Inhibition of PARP/AKT to Intercept Nascent BRCA1/2mut Breast Tumors
